Skip to main content
    O

    Omeros Corporation (OMER)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $13.92
    -2.76 (-16.55%)

    Market Cap: $1.21B

    Last updated: Nov 17, 2026 at 4:36 PM ET

    Omeros Corporation (OMER) P/E Ratio & Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Omeros (OMER) trades at 134.4x trailing earnings and 13.7x sales. Its forward P/E is 16.5x.

    Current Multiples

    Its forward P/E on consensus earnings for the next fiscal year to be reported is below its trailing P/E. Consensus earnings per share are about 714.5% higher than over the last four quarters.

    MultipleValue
    P/E (trailing)134.4x
    Forward P/E16.5x
    Price to sales13.7x
    PEGN/A
    FCF yield-3.6%
    As of Nov 17, 2026

    Valuation History

    Over the 5 of the 10 year ends shown that have a P/S, its P/S ranged from 9.7x in 2016 to 308.9x in 2019.

    Year endPriceP/SP/B
    2025$17.18N/AN/A
    2024$9.88N/AN/A
    2023$3.27N/AN/A
    2022$2.26N/A1.7x
    2021$6.43N/A16.9x
    2020$14.29135.5xN/A
    2019$14.09308.9xN/A
    2018$11.1418.2x0.8x
    2017$19.4313.6xN/A
    2016$9.929.7xN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About OMER

    What is OMER's forward P/E ratio?

    Omeros has a forward P/E ratio of 16.5x.

    What is OMER's price to sales ratio?

    Omeros has a price to sales ratio of 13.7x.